London-based startup Briefly Bio has launched with £1.2 million in pre-seed funding to tackle one of the most pressing issues in scientific research: reproducibility. With an estimated 50% of preclinical research experiments failing to be reproduced, costing the industry over £50 billion annually, Briefly Bio aims to revolutionise how scientists document and share their work.

Technological partnerships The expansion features Cytiva’s Xcellerex XDR Bioreactor single-use system. Silke Fetzer-Rümpler, Senior Vice President, Commercial at Cytiva, noted the system’s scalability and potential to accelerate clinical and commercial milestones.